Just how useful is it to get access to a pharmaceutical company compound? Back in 2012 Dr Richard Mead of the University of Sheffield was one of 15 academic project leaders funded by the MRC to research an alternative use for a compound no longer being developed by AstraZeneca. As we launch the next round of the MRC-Industry Asset Sharing Initiative he tells us how the collaboration has brought together the best of both worlds.
I’m no stranger to the pharmaceutical industry. I spent three years in drug development at Celltech in the early 2000s. But even with my experience, it’s still amazing to be reminded of the resources that pharmaceutical companies have at their fingertips. It sounds obvious, but their access to unique compounds, and their ability to make them, is impressive. Read more